Supplement Regulation Under RFK Jr.: What's Changing

Supplement Regulation Under RFK Jr.: What's Changing

The supplement industry does roughly $60 billion in annual U.S. sales. Until 2025, it operated under rules written in 1994 — rules that gave manufacturers extraordinary latitude, minimal pre-market review, and almost no requirement to prove their products work.

That's starting to change. Under RFK Jr., the FDA is revisiting the core regulatory framework for dietary supplements for the first time in three decades. Some of the proposed changes are long overdue. Some have alarmed supplement advocates. Most are more nuanced than the headlines suggest.

Here's what you need to know.

📖 Related: The regulatory context expands with Health Sovereignty: Your Right to Make Your Own Health Decisions, What Does HHS Do? A Plain-Language Explainer, and FDA Food Ingredient Reviews: The MAHA Movement's Impact.

The Current System: DSHEA and Its Gaps

The Dietary Supplement Health and Education Act (DSHEA) of 1994 is the foundation of U.S. supplement regulation. To understand what's changing, you have to understand what the current system actually does — and doesn't — require.

Under DSHEA, supplement manufacturers:

• Do NOT need FDA approval before selling a product
• Do NOT need to prove their products are effective
• Do NOT need to demonstrate safety before market entry (for ingredients used before 1994)
• CAN make "structure/function" claims (e.g., "supports immune health") without clinical trial evidence
• CANNOT make disease claims (e.g., "treats diabetes") — that requires drug approval

What FDA CAN do under current rules:

• Inspect manufacturing facilities for Good Manufacturing Practice (GMP) compliance
• Require post-market safety reporting for serious adverse events
• Take action against products proven to be adulterated or mislabeled
• Require notification for new ingredients introduced after 1994

The result: a $60 billion industry where a manufacturer can sell a product that doesn't contain what the label says, doesn't work the way it claims, and hasn't been reviewed by any independent authority — as long as it doesn't technically claim to treat a disease.

This is not hypothetical. NSF International and independent testing organizations routinely find that 20-30% of randomly tested supplements are mislabeled — containing less of the active ingredient than claimed, more of it, or entirely different substances.

What RFK Jr. Has Said About Supplements

Kennedy's position on supplements is more nuanced than many assume. He is not anti-supplement. He has been publicly supportive of targeted supplementation — vitamins D3, magnesium, and omega-3s appear favorably in his public statements.

His critique is of the regulatory framework, not the products themselves. In a January 2025 address, he stated:

"Americans are spending billions of dollars on products they have no way to verify are what the label says. The supplement industry has been given 30-year-old rules designed for a market a fraction of today's size. We need modern oversight that protects consumers without stifling innovation."

This framing matters: the stated goal is consumer protection and label accuracy, not restricting access to supplements as a category.

The Proposed Changes: What's Actually on the Table

1. Mandatory Product Listing

Current: Manufacturers are not required to register individual supplement products with the FDA. The FDA may not know a product exists until someone reports an adverse event.

Proposed: A mandatory product listing database — every supplement sold in the U.S. would be required to register its ingredients, dosages, and manufacturer information with FDA before or upon market entry.

Impact: This is a low-intervention, high-transparency change. It wouldn't prevent harmful products from entering the market, but it would give FDA a baseline inventory and make ingredient tracking far more feasible. The supplement industry's opposition is primarily about administrative burden and the precedent it sets.

Consumer benefit: Meaningful. For the first time, FDA would know what products are being sold, enabling more systematic monitoring.

2. New Dietary Ingredient (NDI) Guidance Enforcement

Current: Ingredients introduced after October 15, 1994 (the DSHEA cutoff) technically require FDA notification and a safety history. In practice, this requirement has been largely unenforced. Hundreds of post-1994 ingredients are in supplements without proper NDI filings.

Proposed: Stricter enforcement of existing NDI requirements, with clearer guidance on what constitutes adequate safety evidence.

Impact: This would primarily affect newer ingredients — peptides, plant extracts, novel compounds — that have entered the market without adequate documentation. Many of these are in the "biohacker" and performance supplement category.

Consumer benefit: Moderate. Would remove some high-risk unvalidated ingredients. Would also potentially slow the introduction of genuinely beneficial novel compounds.

3. Enhanced GMP Auditing

Current: FDA inspects manufacturing facilities but has limited resources — the agency conducts roughly 700-800 supplement facility inspections per year against an estimated 8,000+ registered facilities.

Proposed: Increased inspection frequency and third-party GMP auditing requirements for high-risk products.

Impact: Primarily affects product quality and label accuracy. NSF Certified for Sport, Informed Sport, and USP certifications have filled this gap voluntarily — the proposed changes would push more manufacturers toward these standards.

Consumer benefit: Significant for label accuracy. The gap between what a label says and what a product contains is a real and common problem.

4. Expanded Adverse Event Reporting

Current: Manufacturers must report serious adverse events (hospitalizations, deaths) but are not required to track or report less severe events.

Proposed: Expanded adverse event reporting with lower severity thresholds and a consumer-facing reporting pathway.

Impact: Would improve the signal for safety concerns that don't rise to the level of hospitalization but suggest a pattern of harm.

What's NOT Changing (Despite Claims)

Several claims circulating in supplement industry forums and social media overstate what's being proposed:

"FDA is going to require clinical trials for all supplements" — Not in current proposals. The drug approval framework (which requires efficacy trials) is not being extended to supplements. Structure/function claims would still be available without RCT evidence.

"Popular supplements like vitamin D and magnesium will be banned or restricted" — No evidence for this. Well-established, widely used supplements with long safety records are not targeted by any current proposal.

"The FDA will ban supplements that compete with drugs" — This has been a long-standing concern in the supplement industry and is not new to the current administration. The specific boundary between supplements and drugs (particularly around cannabidiol, certain amino acids, and some herbal extracts) is being clarified, not broadly redrawn.

"Kennedy is pro-pharma and wants to gut the supplement industry" — Kennedy's stated position is the opposite. His concern is consumer protection and label accuracy, not restricting supplement access.

The Pharmaceutical Industry Angle: Honest Assessment

One of the supplement industry's consistent arguments against stricter regulation is that the pharmaceutical industry lobbies for it as a competitive protection — creating compliance costs that large pharma can absorb but small supplement companies can't.

This concern has merit. Any regulatory framework creates compliance costs that can disadvantage small manufacturers and create barriers to innovation. It's worth taking seriously.

The counterargument: the current framework has allowed a market where consumers genuinely cannot trust labels, where adulterated products cause hospitalizations, and where ineffective products drain billions from people trying to improve their health. Some regulation is warranted.

The relevant question isn't "should supplements be regulated at all" — they are. It's "what level and type of regulation balances consumer protection with market innovation." The proposed changes skew toward transparency and quality verification rather than efficacy requirements. That's a defensible balance.

What This Means for Your Supplement Choices Right Now

The regulatory changes will take time — FDA rulemaking is a multi-year process. In the interim, the most useful framework for supplement consumers is already available:

Third-Party Certification: Your Best Current Protection

Before any regulatory changes take effect, the voluntary certification programs provide the clearest quality signal:

Rule of thumb: If the supplement you're considering doesn't have at least one of these certifications, the label may not reflect what's actually in the bottle.

Supplements With Strong Evidence Regardless of Regulatory Status

The regulatory debate doesn't change the underlying evidence on specific compounds. These have robust safety and efficacy data:

• Creatine monohydrate — 500+ studies; consistent strength and muscle benefits
• Vitamin D3 — widespread deficiency; well-documented supplementation benefits
• Magnesium glycinate or malate — common deficiency; sleep, muscle, and metabolic benefits
• Omega-3 fatty acids — cardiovascular and anti-inflammatory benefits across multiple RCTs
• Zinc — immune function; common insufficiency in athletes
• Vitamin K2 (MK-7) — bone and cardiovascular health in conjunction with D3

These would remain your highest-value options under any regulatory scenario.

The Bigger Picture: What "MAHA-Aligned" Supplementation Actually Looks Like

The MAHA framework — as applied to supplements — isn't about taking more supplements. It's about:

1. Closing nutritional gaps from food first — Supplements compensate for deficits; they don't replace whole food nutrition
2. Skepticism toward proprietary blends and novel compounds — If you can't verify what's in it or why, skip it
3. Preference for single-ingredient, tested products — Pre-workout blends, fat burners, and "performance stacks" with 15+ ingredients are precisely what the current regulatory gaps enable
4. Third-party verification as non-negotiable — This is the current consumer equivalent of better regulation

The irony is that the most responsible supplement approach — simple, single-ingredient, verified, targeted — requires exactly the quality verification infrastructure that the proposed regulatory changes aim to strengthen.

📖 Related: What to eat instead is covered in The MAHA Diet: What Make America Healthy Again Means for Your Nutrition.

Frequently Asked Questions

Q: Will the new supplement regulations make supplements more expensive? A: Potentially, yes — especially for smaller manufacturers. Compliance costs for mandatory product listing and enhanced GMP auditing would be passed to consumers to some degree. The extent depends on what's ultimately adopted.

Q: Are my current supplements going to be pulled from the market? A: For well-established supplements (vitamins, minerals, common botanicals), this is extremely unlikely. Products with unverified novel ingredients or questionable safety records are the target, not mainstream nutritional supplements.

Q: Should I buy supplements now before regulations change? A: No. Stockpiling is not warranted. Regulatory timelines are long, and the proposed changes would not make currently available, quality supplements unavailable.

Q: How do I know if my current supplements are actually what the label says? A: Use products certified by NSF, Informed Sport, or USP. Or check ConsumerLab.com's independent test database — they've tested hundreds of commercially available products and report both what's claimed and what they actually found.

Q: What's the difference between a supplement and a drug according to FDA? A: The key distinction is intended use. A supplement "supports" structure or function; a drug "treats, cures, or prevents" disease. This distinction gets blurry with some products — particularly those that have documented pharmacological effects. The FDA/supplement boundary is an active area of regulatory clarification.

Conclusion

Supplement regulation in 2025 is changing — gradually, with significant industry resistance, and with outcomes that depend heavily on the FDA's rulemaking process and congressional dynamics. The direction of change is toward greater transparency, label accuracy, and post-market surveillance.

For consumers, the practical implication is the same as always: buy third-party certified products, focus on well-evidenced single ingredients, and treat supplement marketing with healthy skepticism. Those habits protect you regardless of what regulations eventually require.

→ [See our breakdown of supplements actually worth taking — evidence only → /supplements-worth-taking]